Compare Cipla with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PIRAMAL ENTERPRISES - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PIRAMAL ENTERPRISES CIPLA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 23.3 15.5 150.2% View Chart
P/BV x 2.4 1.0 241.6% View Chart
Dividend Yield % 0.7 1.8 37.6%  

Financials

 CIPLA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    CIPLA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
CIPLA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6783,303 20.5%   
Low Rs4841,797 26.9%   
Sales per share (Unadj.) Rs198.2716.5 27.7%  
Earnings per share (Unadj.) Rs18.579.7 23.2%  
Cash flow per share (Unadj.) Rs35.0107.9 32.4%  
Dividends per share (Unadj.) Rs3.0028.00 10.7%  
Dividend yield (eoy) %0.51.1 47.0%  
Book value per share (Unadj.) Rs186.31,477.5 12.6%  
Shares outstanding (eoy) m805.70184.45 436.8%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.93.6 82.3%   
Avg P/E ratio x31.432.0 98.0%  
P/CF ratio (eoy) x16.623.6 70.3%  
Price / Book Value ratio x3.11.7 180.7%  
Dividend payout %16.235.1 46.1%   
Avg Mkt Cap Rs m468,031470,292 99.5%   
No. of employees `00022.67.8 289.6%   
Total wages/salary Rs m28,56522,504 126.9%   
Avg. sales/employee Rs Th7,053.116,899.4 41.7%   
Avg. wages/employee Rs Th1,261.52,877.7 43.8%   
Avg. net profit/employee Rs Th659.11,879.9 35.1%   
INCOME DATA
Net Sales Rs m159,710132,153 120.9%  
Other income Rs m4,7663,128 152.4%   
Total revenues Rs m164,475135,281 121.6%   
Gross profit Rs m30,97366,290 46.7%  
Depreciation Rs m13,2635,202 255.0%   
Interest Rs m1,68444,097 3.8%   
Profit before tax Rs m20,79120,119 103.3%   
Minority Interest Rs m-1723,194 -5.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6958,611 66.1%   
Profit after tax Rs m14,92414,701 101.5%  
Gross profit margin %19.450.2 38.7%  
Effective tax rate %27.442.8 64.0%   
Net profit margin %9.311.1 84.0%  
BALANCE SHEET DATA
Current assets Rs m124,266122,742 101.2%   
Current liabilities Rs m37,715310,810 12.1%   
Net working cap to sales %54.2-142.3 -38.1%  
Current ratio x3.30.4 834.3%  
Inventory Days Days9123 392.9%  
Debtors Days Days9539 244.2%  
Net fixed assets Rs m105,190116,904 90.0%   
Share capital Rs m1,611369 436.8%   
"Free" reserves Rs m148,511272,161 54.6%   
Net worth Rs m150,123272,530 55.1%   
Long term debt Rs m38,301270,196 14.2%   
Total assets Rs m239,633856,261 28.0%  
Interest coverage x13.31.5 916.4%   
Debt to equity ratio x0.31.0 25.7%  
Sales to assets ratio x0.70.2 431.8%   
Return on assets %6.96.9 100.9%  
Return on equity %9.95.4 184.3%  
Return on capital %11.812.4 95.3%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41015,200 377.7%   
Fx outflow Rs m19,0414,889 389.5%   
Net fx Rs m38,36810,312 372.1%   
CASH FLOW
From Operations Rs m16,911-115,975 -14.6%  
From Investments Rs m-16,687-8,265 201.9%  
From Financial Activity Rs m-3,487107,525 -3.2%  
Net Cashflow Rs m-3,451-16,650 20.7%  

Share Holding

Indian Promoters % 16.0 52.9 30.2%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.0 305.0%  
FIIs % 23.7 26.6 89.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 16.5 158.8%  
Shareholders   161,166 93,274 172.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ELDER PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 18, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS